Control of ocular tumor growth and metastatic spread by soluble and membrane Fas ligand

Cancer Research

Volumn 67, Issue 24, 2007, Pages 11951-11958

  Gregory, Meredith S ^a   Saff, Rebecca R ^b   Marshak Rothstein, Ann ^b   Ksander, Bruce R ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; METALLOPROTEINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CONTROL; CELL CLONE; CONTROLLED STUDY; EYE TUMOR; FEMALE; GENETIC TRANSFECTION; INFLAMMATION; LIVER METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TUMOR GROWTH; TUMOR IMMUNITY; WILD TYPE;

ANIMALS; CELL MEMBRANE; EYE NEOPLASMS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENES, REPORTER; INFLAMMATION; LEUKEMIA L5178; MICE; MICE, INBRED DBA; NEOPLASM METASTASIS; TRANSFECTION;

EID: 37549020752     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0780     Document Type: Article

References (33)

1. Medawar PB. Immunity to homologous grafted skin. III the fate of skin homografts transplanted to the brain, subcutaneous skin, and to the anterior chamber of the eye. Br Exp Pathol 1948;29:58-69.
2. Griffith T, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas Ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-92.
3. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 Ligand in preventing graft rejection. Nature 1995;377:630-2.
4. Saas P, Walker PR, Hahne M, et al. Fas ligand expression by astrocytoma in vivo; maintaining immune privilege in the brain? J Clin Invest 1997;99:1173-8.
5. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997;158:4122-8.
6. Niederkorn JY. See no evil, do no evil; the lessons of immune privilege. Nat Immunol 2006;4:354-9.
7. Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol 2003;11:879-90.
8. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The fas counterattack: as mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996;184:1075-82.
9. Chen PW, Ksander BR. Immune privilege, tumors, and the eye. In Streilein JW, editor. Immune Response and The Eye, Chemical Immunology. Basel: Karger; 1999. p. 137-58.
10. Nagata S, Goldstein P. The Fas death factor. Science 1995;267:1449-56.
11. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
12. Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777-83.
13. Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteinases. Eur J Immunol 1995;25:2303-7.
14. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998;4:31-6.
15. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000;191:1209-20.
16. Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med 1997;186:2045-50.
17. Gregory MS, Repp AC, Holhbaum AM, Saff RR, Marshak-Rothstein A, Ksander BR. Membrane Fas ligand activates innate immunity and terminates ocular immune privilege. J Immunol 2002;169:2727-35.
18. Streilein JW, Niederkorn JY. Induction of anterior chamber associated immune deviation requires an intact, functional spleen. J Exp Med 1981;153:1058-67.
19. Niederkorn J, Streilein JW, Shadduck JA. Deviant immune responses to allogeneic tumors injected intra-camerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1980;20:355-63.
20. Matrisain LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
21. Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences. Curr Opin Cell Biol 1998;10:602-8.
22. Moses MA, Marikovsky M, Harper JW, et al. Temporal study of the activity of matrix metalloproteinases and their endogenous inhibitors during wound healing. J Cell Biochem 1996;60:379-86.
23. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human fas ligand. Arch Biohem Biophys 2002;408:155-61.
24. Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Ret Eye Res 2002;21:1-14.
25. Kahari VM, Saarialho-kere U. Matrix metalloproteinases and their inhibitors in tumor growth and invasion. Ann Med 1999;31:34-45.
26. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
27. Shiomi T, Okada Y. MT1-MMP and MMP7 in invasion and metastasis of human cancers. Can Met Rev 2003;22:145-52.
28. Zeng Z-S, Shu W-P, Chen AM, Guillem JG. Matrix metalloproteinase-7 expression in colorectal cancer liver metastases: evidence for involvement of MMP-7 activation in human cancer metastases. Clin Cancer Res 2002;8:144-8.
29. Ueno H, Yamashita K, Aazumano I, Inoue M, Okada Y. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas. Int J Cancer 1999;84:470-7.
30. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase-7 (matrilysin) in human gastric carcinomas; implications for vessel invasion and metastasis. Int J Cancer 1998;79:187-94.
31. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Current Biol 1994;9:1441-7.
32. Baker AH, Edwards DR, Murphy G. Metalloproteainase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-27.
33. Sethi CS, Bailey TAA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000;84:654-66.